India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market.

Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, order wins and acquisitions, here’s a quick look at which stocks will be ...

The facility aims to advance AI in drug discovery, clinical trials, and patient care. The company plans to launch its Dengue vaccine in India by 2026 and expand its focus on inflammation, oncology, ...

Pfizer and Intel have sent warnings to the European Chemicals Agency which is considering the move Pfizer pharmaceuticals wrote that a total ban would threaten the viability of this sector.

AstraZeneca CFO Aradhana Sarin promised Phase III readouts and revenue growth in 2025 despite ongoing investigations of its Chinese operations. Credit: Bloomberg/ Getty Images AstraZeneca says a ...

As I step into Rajeev Juneja’s office at Mankind Pharma’s Delhi headquarters ... such as Sanofi India, Cipla, and Zydus Lifesciences. With the scale that the OTC vertical has achieved ...

Pharmaceutical manufacturing encompasses all processes involved in the manufacturing and production of biological and medical products, botanical drugs, and herbs, as well as other pharmaceutical ...

The growing investment in India's CDMO sector indicates confidence in India’s pharmaceutical sector and its potential - A detailed analysis. With the U.S. increasingly adopting an anti-China ...

Each year at the J.P. Morgan Healthcare Conference, pharma CEOs are tasked with assuring and convincing investors that they’ve positioned their companies to overcome expected challenges.

Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

Harry Sumnall receives funding from public grant awarding bodies for alcohol and other drugs research, and fees from (international) not-for-profit organisations and government departments for ...

Phio Pharmaceuticals shares more than tripled after the company said it saw positive results from its Phase 1b trial for its cancer treatment PH-762. Shares were recently up more than 270% to $6. ...